Emerging oral therapies for multiple sclerosis

International Journal of Clinical Practice

Volumn 61, Issue 11, 2007, Pages 1922-1930

  Cohen, B A ^a,c   Rieckmann, P ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BG 000012; BG 00012; CLADRIBINE; FINGOLIMOD; GLATIRAMER; IBUPROFEN; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 4; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; PARACETAMOL; PLACEBO; ROQUINIMEX; TERIFLUNOMIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS B; HERPES ZOSTER; HUMAN; INJECTION SITE NECROSIS; INJECTION SITE REACTION; LONG TERM CARE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSING REMITTING MULTIPLE SCLEROSIS; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 35348845728     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01561..x     Document Type: Review

References (102)

1. Fontoura P, Steinman L, Miller A. Emerging therapeutic targets in multiple sclerosis. Curr Opin Neurol 2006 19 : 260 6.
2. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996 6 : 259 74.
3. Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004 56 : 308.
4. Kieseier BC, Wiendl H. Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 2007 21 : 483 502.
5. Avonex®. Summary of Product Characteristics. UK. http://emc. medicines.org.uk (accessed 8 March 2007).
6. Betaferon® Summary of Product Characteristics, UK. http://emc.medicines.org.uk (accessed 10 May 2007).
7. Rebif® Summary of Product Characteristics, UK. http://emc.medicines. org.uk (accessed 3 May 2006).
8. Copaxone® Summary of Product Characteristics, UK. http://emc.medicines.org.uk (accessed 23 March 2006).
9. Tysabri® Summary of Product Characteristics, UK. http://emc. medicines.org.uk (accessed 19 June 2007).
10. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006 38 : 167 71.
11. Mohr DC, Cox D, Merluzzi N. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications. Mult Scler 2005 11 : 182 5.
12. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001 23 : 125 32.
13. Cockshott WP, Thompson GT, Howlett LJ, Seeley ET. Intramuscular or intralipomatous injections? N Engl J Med 1982 307 : 356 8.
14. Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002 59 : 1496 506.
15. Rio J, Porcel J, Tellez N et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005 11 : 306 9.
16. Samuel L, Lowenstein EJ. Recurrent injection site reactions from interferon beta 1-b. J Drugs Dermatol 2006 5 : 366 7.
17. Cramer JA, Cuffel BJ, Divan V, Al-Sabbagh A, Glassman M. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006 113 : 156 62.
18. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003 61 : 551 4.
19. Limmroth V, Malessa R, Zettl UK et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol 2007 254 : 67 77.
20. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998 352 : 1498 504.
21. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995 45 : 1277 85.
22. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005 11 : 585 91.
23. Giovannoni G, Barbarash O, Casset-Semanez F et al. Immunogenicity and tolerability of an investigational formulation of interferon beta-1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically-controlled, Phase IIIb study in adults with multiple sclerosis. Clin Ther 2007 29 : 1128 450.
24. Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care 1998 4 : 1563 8.
25. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva : World Health Organization, 2002.
26. Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM. Adherence in chronic disease. Annu Rev Nurs Res 2000 18 : 48 90.
27. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005 4 : CD000011.
28. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004 42 : 200 9.
29. World Health Organization. Adherence to Long-term Therapies: Evidence for Action. Geneva : WHO, 2003.
30. Sackett DL, Snow JC. The magnitude of compliance and non-compliance. In : Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, MD : The Johns Hopkins University Press, 1979 : 11 22.
31. Sawyer SM, Aroni RA. Sticky issue of adherence. J Paediatr Child Health 2003 39 : 2 5.
32. Cluss PA, Epstein LH. The measurement of medical compliance in the treatment of disease. In : Karoly P, ed. Measurement Strategies in Health Psychology. New York : John Wiley & Sons, 1985 : 403 32.
33. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001 33 : 865 72.
34. Svensson S, Kjellgren KI, Ahlner J, Saljo R. Reasons for adherence with antihypertensive medication. Int J Cardiol 2000 76 : 157 63.
35. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998 279 : 1977 83.
36. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003 6 : 566 73.
37. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002 288 : 2880 3.
38. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997 54 : 531 3.
39. Mohr DC, Goodkin DE, Likosky W, Gatto N, Neilley LK, Griffin C, et al Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996 2 : 222 6.
40. Cohen BA. Adherence to disease-modifying therapy for multiple sclerosis. Int J MS Care 2006 Suppl. 1 : 32 7.
41. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 353 : 487 97.
42. Webb DG, Horne R, Pinching AJ. Treatment-related empowerment: preliminary evaluation of a new measure in patients with advanced HIV disease. Int J STD AIDS 2001 12 : 103 7.
43. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000 160 : 2101 7.
44. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997 15 : 110 5.
45. Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006 17 : 239 45.
46. Fallowfield L, Atkins L, Catt S et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006 17 : 205 10.
47. Jani R, Triplitt C, Reasner C, Defronzo RA. First approved inhaled insulin therapy for diabetes mellitus. Expert Opin Drug Deliv 2007 4 : 63 76.
48. Freemantle N, Blonde L, Duhot D et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005 28 : 427 8.
49. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004 27 : 2622 7.
50. Hollander PA, Blonde L, Rowe R et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004 27 : 2356 62.
51. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004 27 : 1318 23.
52. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001 23 : 1311 20.
53. Filippi M, Wolinsky JS, Comi G. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 2006 5 : 213 20.
54. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000 47 : 273 89.
55. Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 1995 272 : 460 8.
56. Zeyda M, Poglitsch M, Geyeregger R et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005 52 : 2730 9.
57. O'Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006 66 : 894 900.
58. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004 156 : 3 9.
59. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005 64 : 987 91.
60. Tan IL, Lycklama a Nijeholt GJ, Polman CH, Ader HJ, Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler 2000 6 : 99 104.
61. Mullershausen F, Craveiro LM, Shin Y et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 2007 doi:10.1111/j.1471-4159.2007.04629.x.
62. Payne SG, Oskeritzian CA, Griffiths R et al. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1- phosphate receptors. Blood 2007 109 : 1077 85.
63. Gonsette RE. New immunosuppressants with potential implication in multiple sclerosis. J Neurol Sci 2004 223 : 87 93.
64. Segoloni GP, Quaglia M. New immunosuppressive drugs for prevention and treatment of rejection in renal transplant. J Nephrol 2006 19 : 578 86.
65. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006 355 : 1124 40.
66. Kappos L, Miller D, MacManus DG et al. BG00012, a Novel Oral Fumarate, is Effective in Patients with Relapsing-Remitting Multiple Sclerosis. Madrid, Spain : European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS), 2006.
67. Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 1998 196 : 223 30.
68. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999 141 : 424 9.
69. Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A 2004 101 (Suppl. 2 14593 8.
70. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996 93 : 1716 20.
71. Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci U S A 1984 81 : 2232 6.
72. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2- Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992 80 : 587 92.
73. Juliusson G, Heldal D, Hippe E et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995 13 : 989 95.
74. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998 92 : 1918 26.
75. Ogura M, Morishima Y, Kobayashi Y et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol 2004 80 : 267 77.
76. Krance RA, Hurwitz CA, Head DR et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001 19 : 2804 11.
77. Dimopoulos MA, Kantarjian H, Weber D et al. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994 12 : 2694 8.
78. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997 32 : 120 31.
79. Valencak J, Trautinger F, Fiebiger WC, Raderer M. Complete remission of chronic plaque psoriasis and gastric marginal zone B-cell lymphoma of MALT type after treatment with 2-chlorodeoxyadenosine. Ann Hematol 2002 81 : 662 5.
80. Schirmer M, Mur E, Pfeiffer KP, Thaler J, Konwalinka G. The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scand J Rheumatol 1997 26 : 376 9.
81. Davis JC Jr., Austin H 3rd., Boumpas D et al. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998 41 : 335 43.
82. Duchini A, Younossi ZM, Saven A, Bordin GM, Knowles HJ, Pockros PJ. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000 31 : 292 6.
83. Pless M, Gratwohl A, Tichelli A, Speck B, Betticher DC. 2-Chlorodeoxyadenosine as treatment of severe acute graft-versus-host disease. Blood 1994 84 : 987 9.
84. Plunkett W, Gandhi V. Pharmacology of purine nucleoside analogues. Hematol Cell Ther 1996 38 (Suppl. 2 S67 74.
85. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992 340 : 952 6.
86. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000 54 : 1145 55.
87. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999 111 : 35 44.
88. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994 344 : 9 13.
89. Beutler E, Sipe J, Romine J, McMillan R, Zyroff J, Koziol J. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol 1996 33 : 45 52.
90. Janiec K, Wajgt A, Kondera-Anasz Z. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Med Sci Monit 2001 7 : 93 8.
91. Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005 5 : 721 7.
92. Leuschen MP, Filipi M, Healey K. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. Mult Scler 2004 10 : 636 42.
93. Rio J, Nos C, Bonaventura I et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology 2004 63 : 525 8.
94. Brochet B, Lemaire G, Beddiaf A. Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices. Rev Neurol (Paris) 2006 162 : 735 40.
95. Baum K. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b-results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis. J Int Med Res 2006 34 : 1 12.
96. Phillips JT, Rice G, Frohman E et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 2004 26 : 511 21.
97. Pfohl DC. A Multiple Sclerosis (MS) Center Injection Training Program. Axone 1997 19 : 29 33.
98. Keating MM, Ostby PL. Education and self-management of interferon beta-1b therapy for multiple sclerosis. J Neurosci Nurs 1996 28 : 350 2, 357 8.
99. Sidorenko TV, Khachanova NV, Boiko AN. [A wide support of patients with multiple sclerosis promotes success of long-term therapy]. Zh Nevrol Psikhiatr Im S S Korsakova 2006 3 : 96 100.
100. Denis L, Namey M, Costello K et al. Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach. J Neurosci Nurs 2004 36 : 10 22.
101. Rieckmann P. DMDs: Balancing Expectations and Adherence to Treatment. Thessaloniki, Greece : European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Sept 28-1 Oct 2005 (Abstract 60).
102. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate- modifiers of lymphocyte migration. N Engl J Med 2006 355 : 1088 91.